RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting [Yahoo! Finance]
RenovoRx, Inc. (RNXT)
Company Research
Source: Yahoo! Finance
Platform's Potential to Increase Local Drug Potency and Reduce Systemic Exposure and Common Side Effects of Chemotherapy MOUNTAIN VIEW, Calif., April 23, 2026 (GLOBE NEWSWIRE) RenovoRx, Inc . (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, is pleased to announce that an abstract submission from a pharmacokinetic (PK) and pharmacodynamic sub-study of its ongoing Phase III TIGeR-PaC clinical trial locally advanced pancreatic cancer has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The abstract, entitled “The TIGeR-PaC Phase 3 III Clinical Trial Examining Intra-Arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic and Pharmacodynamic Sub-Study ” explores RenovoRx's lead product candidate, intra-arterial delivery of gemcitabine via RenovoCath (known as IAG), and
Show less
Read more
Impact Snapshot
Event Time:
RNXT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNXT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNXT alerts
High impacting RenovoRx, Inc. news events
Weekly update
A roundup of the hottest topics
RNXT
News
- RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ETGlobeNewswire
- RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual MeetingGlobeNewswire
- Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific MeetingGlobeNewswire
- RenovoRx (RNXT) had its price target raised by Ascendiant Capital Markets from $13.00 to $13.50. They now have a "buy" rating on the stock.MarketBeat
- RenovoRx (RNXT) had its "buy" rating reaffirmed by HC Wainwright. They now have a $3.00 price target on the stock.MarketBeat
RNXT
Earnings
- 5/15/25 - In-Line
RNXT
Sec Filings
- 4/28/26 - Form EFFECT
- 4/27/26 - Form 424B3
- 4/27/26 - Form SCHEDULE
- RNXT's page on the SEC website